Duke University: Astrocytoma trials
The registry lists 27 Astrocytoma studies with Duke University as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 14Phase 2 16No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)CompletedNCT00671970Phase 2Results posted
- Ph II Bevacizumab + Etoposide for Pts w Recurrent MGCompletedNCT00612430Phase 2Results posted
- Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant GliomaCompletedNCT00301873Phase 2Results posted
- Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + TemozolomideCompletedNCT00616005Phase 2
- Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant GliomaCompletedNCT00613093Phase 2
- PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant GliomasCompletedNCT00612651Phase 1
- Ph I SU011248 + Irinotecan in Treatment of Pts w MGCompletedNCT00611728Phase 1
- Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant GliomaCompletedNCT00387933Phase 1
- Imatinib Mesylate and Temozolomide in Treating Patients With Malignant GliomaCompletedNCT00354068Phase 1
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant GliomaCompletedNCT00352521Phase 2
- Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory GliomasCompletedNCT00268359Phase 2
- Temozolomide and O6-benzylguanine in Treating Patients With Newly Diagnosed, Recurrent, or Progressive Anaplastic GliomaCompletedNCT00006474Phase 1
- Genetic Study in Patients Receiving Treatment for Hodgkin's Disease or Childhood Brain TumorCompletedNCT00006342
- Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS TumorsCompletedNCT00005955Phase 2
- Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid TumorsCompletedNCT00005952Phase 1/2
- Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant GliomaCompletedNCT00005951Phase 1
- Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive GliomaCompletedNCT00005081Phase 2
- Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain TumorsCompletedNCT00003478Phase 1/2
- Carmustine in Treating Adults With Recurrent Supratentorial Low-Grade GliomaCompletedNCT00003467Phase 2
- Temozolomide in Treating Patients With Progressive Low-Grade GliomaCompletedNCT00003466Phase 2
- Carmustine Wafers Plus Irinotecan in Treating Patients With Recurrent Supratentorial High Grade GliomasCompletedNCT00003463Phase 1
- Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain TumorsCompletedNCT00003461Phase 1/2
- Carmustine Plus O(6)-Benzylguanine in Treating Patients With Recurrent or Progressive Gliomas of the BrainCompletedNCT00003348Phase 1
- Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain TumorsCompletedNCT00002754Phase 1
- Monoclonal Antibody Therapy in Treating Patients With Recurrent GliomasCompletedNCT00002753Phase 1
- Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain CancersCompletedNCT00002752Phase 1/2
- Carboplatin in Patients With Progressive GliomasCompletedNCT00002749Phase 2